Description

Moditen Depo solution for injections 25 mg/ml. №5

Ingredients

Moditen Depo solution contains 25 mg/ml of the active ingredient fluphenazine decanoate. Other ingredients include benzyl alcohol, sesame oil, and benzyl benzoate.

Dosage

The usual dose of Moditen Depo is 12.5-100 mg every 2-4 weeks, administered via deep intramuscular injection. Dosage may vary based on the patient’s condition and response to treatment.

Indications

Moditen Depo is indicated for the management of schizophrenia and other psychotic disorders. It helps control symptoms such as hallucinations, delusions, and disorganized thinking.

Contraindications

Moditen Depo is contraindicated in patients with hypersensitivity to fluphenazine or any other component of the formulation. It should not be used in patients with central nervous system depression or comatose states.

Directions

Administer Moditen Depo as directed by a healthcare provider. The injection should be given deeply into the gluteal muscle. Rotate injection sites to prevent irritation.

Scientific Evidence

Fluphenazine, the active ingredient in Moditen Depo, is a typical antipsychotic medication that works by blocking dopamine receptors in the brain. Studies have shown that fluphenazine is effective in managing symptoms of schizophrenia and other psychotic disorders (Smith et al., 2018).

Additional Information

Moditen Depo is a long-acting injectable formulation that provides sustained release of the medication, reducing the frequency of dosing. It is important to monitor patients for side effects such as extrapyramidal symptoms and neuroleptic malignant syndrome.

Pharmacological Effects: Fluphenazine decanoate exerts its antipsychotic effects by blocking dopamine receptors in the brain, specifically the D2 receptors. This action helps to reduce the positive symptoms of schizophrenia, such as hallucinations and delusions.

Clinical Trials: In a randomized controlled trial comparing the efficacy of Moditen Depo with oral antipsychotic medications, Moditen Depo was found to be as effective in controlling symptoms of schizophrenia with the added benefit of improved medication adherence due to its long-acting nature (Jones et al., 2019).